Pharmaceutical - Johnson & Johnson, Pharmaceutical

Filter

Popular Filters

1 to 25 of 260 results

Public-private partnerships vital to advance Ebola treatment pipeline, says analyst

16-10-2014

In the battle against Ebola, incentives from governments and health care policymakers have been and will…

Anti-viralscAd3-ZEBOVGlaxoSmithKlineJohnson & JohnsonMapp BiopharmaceuticalNewLink GeneticsPharmaceuticalResearch

Johnson & Johnson third-qtr results beat analysts’ expectations

14-10-2014

US health care giant Johnsons & Johnson, the first in the sector to report third-quarter 2014 financial…

FinancialJohnson & JohnsonPharmaceutical

Johnson & Johnson to acquire Alios BioPharma

Johnson & Johnson to acquire Alios BioPharma

30-09-2014

US health care giant Johnson & Johnson has signed a definitive agreement to acquire Alios BioPharma,…

AL-8176Alios BioPharmaAnti-viralsJohnson & JohnsonMergers & AcquisitionsPharmaceuticalUSA

ESMO 2014: Novartis’ Afinitor; and Janssen’s Zytiga

ESMO 2014: Novartis’ Afinitor; and Janssen’s Zytiga

28-09-2014

Swiss pharma major Novartis on Saturday presented final results on overall survival (OS) from a Phase…

AfinitorJanssenJohnson & JohnsonNovartisOncologyPharmaceuticalResearchSpainZytiga

UK NICE consults on draft guidance for hepatitis C drug Olysio

UK NICE consults on draft guidance for hepatitis C drug Olysio

18-09-2014

In draft guidance published today UK drugs watchdog the National Institute for Health and Care Excellence…

Anti-viralsJanssenJohnson & JohnsonOlysioPharmaceuticalPricingRegulationUK

Added benefit for certain patients found by IQWiG with Janssen’s Olysio

Added benefit for certain patients found by IQWiG with Janssen’s Olysio

15-09-2014

In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products…

Anti-viralsGermanyJanssenJohnson & JohnsonOlysioPharmaceuticalPricingRegulation

Johnson & Johnson fast-tracking its Ebola efforts with Crucell and Bavarian Nordic

Johnson & Johnson fast-tracking its Ebola efforts with Crucell and Bavarian Nordic

04-09-2014

US health care giant Johnson & Johnson will fast-track the development of an Ebola vaccine in response…

Antibiotics and Infectious diseasesBavarian NordicCrucellEbolaJohnson & JohnsonMicrobiologyPharmaceuticalResearch

New studies planned to further expand indications for Xarelto

New studies planned to further expand indications for Xarelto

29-08-2014

German pharma major Bayer and partner Janssen Research & Development, a unit of US health care giant…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalResearchXarelto

FDA approves Janssen’s Invokamet for diabetes

09-08-2014

The US Food and Drug Administration has approved US health care giant Johnson & Johnson subsidiary Janssen…

DiabetesInvokametInvokanaJanssenJohnson & JohnsonPharmaceuticalRegulationUSA

Global epileptic anticonvulsants market - 2014-2020

Global epileptic anticonvulsants market - 2014-2020

16-07-2014

North America dominates the global epileptic anticonvulsants market and is followed by Europe, according…

Abbott LaboratoriesAsia PacificBusiness FinanceEpilepsyGlaxoSmithKlineGlobalHealth Medical PharmaHealth Medical PharmaJohnson & JohnsonMarkets & MarketingNeurologicalNovartisPfizerPharmaceuticalUCB

New products drive 2nd-qtr growth for Johnson & Johnson

New products drive 2nd-qtr growth for Johnson & Johnson

15-07-2014

Global health care products giant Johnson & Johnson, the first pharma to report second-quarter 2014 financial…

Business FinanceFinancialJohnson & JohnsonMonoclonal antibodiesPharmaceuticalPrednisoneUSA

Added benefit of Invokana in type 2 diabetes is not proven, says IQWiG

Added benefit of Invokana in type 2 diabetes is not proven, says IQWiG

17-06-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

DiabetesGermanyInvokanaJanssen-CilagJohnson & JohnsonPharmaceuticalPricingRegulation

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

12-06-2014

ViiV Healthcare today announced that they have entered into an agreement with Janssen R&D Ireland, a…

Anti-viralsEdurantGlaxoSmithKlineJanssenJohnson & JohnsonLicensingPharmaceuticalResearchTivicayViiV Healthcare

Targeted therapies must show cost effectiveness to compete with biosimilars in Brazil and Mexico

Targeted therapies must show cost effectiveness to compete with biosimilars in Brazil and Mexico

10-06-2014

Certain targeted therapies enjoy extensive but incomplete coverage in Brazil and Mexico through complex…

BiosimilarsBrazilJohnson & JohnsonMabTheraMexicoOncologyPharmaceuticalPricingRocheVelcade

EU approval for Janssen's Sylvant to treat patients with MCD

EU approval for Janssen's Sylvant to treat patients with MCD

08-06-2014

The European Commission (EC) has approved the use of Janssen-Cilag International's Sylvant (siltuximab)…

EuropeJanssen-CilagJohnson & JohnsonPharmaceuticalRare diseasesRegulationSylvant

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

29-05-2014

In addition to an improvement in median overall survival (MOS), delayed disease progression is one of…

Astellas PharmaBayerEuropeJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalUSAXofigoXtandiZytiga

NICE gives negative guidance on Janssen’s Stelara for psoriatic arthritis

NICE gives negative guidance on Janssen’s Stelara for psoriatic arthritis

28-05-2014

US health care giant Johnson & Johnson subsidiary Janssen today received a negative opinion from UK watchdog…

DermatologicalsInflammatory diseasesJanssenJohnson & JohnsonPharmaceuticalPricingRegulationStelaraUK

UK’s NICE backs Janssen’s Invokana for type 2 diabetes

16-05-2014

Janssen, a subsidiary of US health care giant Johnson & Johnson, said today that it welcomes the publication…

DiabetesInvokanaJanssenJohnson & JohnsonPharmaceuticalPricingRegulationUK

Negative NICE draft guidance on Janssen’s Zytiga for prostate cancer

Negative NICE draft guidance on Janssen’s Zytiga for prostate cancer

14-05-2014

In draft guidance published this morning, the UK drugs watchdog the National Institute for Health and…

JanssenJohnson & JohnsonOncologyPharmaceuticalPricingRegulationUKZytiga

Janssen expands accord with IPM for dapivirine in prevention of sexual transmission of HIV

08-05-2014

Janssen R&D Ireland, a unit of US health care giant Johnson & Johnson, has expanded its collaboration…

Anti-viralsJanssenJohnson & JohnsonPharmaceuticalResearch

Once-monthly Invega Sustenna reduces risk of relapse in schizoaffetive disorder

Once-monthly Invega Sustenna reduces risk of relapse in schizoaffetive disorder

07-05-2014

US health care giant Johnson & Johnson subsidiary Janssen Pharmaceuticals has released positive results…

Invega SustennaJanssenJohnson & JohnsonNeurologicalPharmaceuticalRegulationResearch

1 to 25 of 260 results

Parexel

Parexel

Back to top